Carregant...
Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
Since 2005, an abundance of targeted agents has been approved for the treatment of metastatic renal cell carcinoma (mRCC), without any specification as to what may be the most optimal first-line and second-line sequence. Hence, our objective was to critically examine the evidence supporting the use...
Guardat en:
| Publicat a: | Int J Nephrol Renovasc Dis |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4219683/ https://ncbi.nlm.nih.gov/pubmed/25378943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S48496 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|